THE Russian Federal Service on
Surveillance in Healthcare and
Social Development has become
the first agency to approve Merck
Serono’s Movectro (oral cladribine)
for the treatment of relapseremitting
MS (RRMS) patients.
The world’s first oral diseasemodifying
MS therapy, the drug is
set to take on the market leading
interferon betas and Copaxone
(glatiramer acetate, Teva) MS
treatments.
In the US, Novartis’ own oral
disease-modifying MS therapy
Gilenia (fingolimod) is set to beat
Movectro to the market, having
already received unanimous
backing by the FDA advisory panel
for the treatment of relapse-remitting
MS (RRMS) patients, back in June.
At present Movectro has not yet
received the US FDA advisory panel
nod.The above article was sent to subscribers in Pharmacy Daily's issue from 16 Jul 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Jul 10
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.